BioCentury | Apr 4, 2020
Product Development

Dealmaking in a pandemic: partnerships that could expedite COVID-19 countermeasures

COVID-19 may be putting the brakes on a broad swath of biopharma deals, but it has also triggered a host of partnerships for coronavirus countermeasures, pushing vaccine deals to their highest numbers in years. Many...
BioCentury | Apr 4, 2020
Finance

Investors are seeking only one thing: a sign the pandemic tide is shifting

The usual clinical and commercial catalysts are taking a back seat in the second quarter as buysiders are almost solely focused on COVID-19 milestones that will stabilize the market. On the other hand, the virtual...
BioCentury | Apr 3, 2020
Product Development

COVID-19: manufacturing mAbs in patients

The urgency and scale of the coronavirus outbreak could drive progress in an emerging therapeutic strategy suited to rapid development and distribution -- encoding of antibodies in RNA or DNA. Neutralizing mAbs against SARS-CoV-2 have...
BioCentury | Apr 1, 2020
Finance

Pandion’s immune-regulating platform attracts $80M B round

Pandion raised $80 million in a series B round, triggered by a pancreas-focused partnership with Astellas and the clinical debut of its lead immune modulator. The modularity attracted Access Biotechnology to co-lead the round with...
BioCentury | Mar 26, 2020
Regulation

FDA finally approves ozanimod for MS, satisfying first criterion for Bristol-Celgene CVR; launch delayed due to COVID-19

FDA’s approval of Celgene’s multiple sclerosis drug Zeposia ozanimod represents the first domino to fall among three that could lead to a big payout for Celgene’s former shareholders, who would be owed a contingent value...
BioCentury | Mar 26, 2020
Product Development

COVID-19 roundup: Grifols partners with BARDA, FDA on convalescent plasma; plus Vir, Sorrento, Ascletis, BMS and Ipsen

On the heels of FDA guidance for compassionate use of convalescent plasma for COVID-19, Grifols announced on Wednesday a partnership with the U.S. government to develop the therapy. Meanwhile, Vir and Sorrento are advancing their...
BioCentury | Mar 24, 2020
Product Development

Positive data for intrathecally delivered Zolgensma could broaden its patient population

The latest data on Novartis’ Zolgensma could help solidify and possibly expand the gene therapy’s position in the SMA market as the company prepares for a potential new entrant in the coming months. During a...
BioCentury | Mar 20, 2020
Finance

COVID stocks spike as market volatility continues

As the broader markets continue to tumble amidst the COVID-19 pandemic, several biotechs at the center of the race to develop countermasures have seen their valuations swing wildly since the crisis began to unfold in...
BioCentury | Mar 20, 2020
Emerging Company Profile

Eikonizo: brain-penetrant HDAC inhibitors for neurodegeneration

Eikonizo aims to shore up axonal transport to treat neurodegenerative diseases, starting with ALS; and to de-risk its programs, the company is developing a companion PET tracer to confirm target engagement in vivo.   The...
BioCentury | Mar 19, 2020
Product Development

Trials, in-hospital treatments and guidances hit snags in the wake of COVID-19

As vaccine and therapeutic companies ramp up clinical trials for COVID-19, other biotechs are halting trials to protect patients and to preserve hospital resources. The ripple effects of the pandemic are also beginning to play...
Items per page:
1 - 10 of 4851
BioCentury | Apr 4, 2020
Product Development

Dealmaking in a pandemic: partnerships that could expedite COVID-19 countermeasures

COVID-19 may be putting the brakes on a broad swath of biopharma deals, but it has also triggered a host of partnerships for coronavirus countermeasures, pushing vaccine deals to their highest numbers in years. Many...
BioCentury | Apr 4, 2020
Finance

Investors are seeking only one thing: a sign the pandemic tide is shifting

The usual clinical and commercial catalysts are taking a back seat in the second quarter as buysiders are almost solely focused on COVID-19 milestones that will stabilize the market. On the other hand, the virtual...
BioCentury | Apr 3, 2020
Product Development

COVID-19: manufacturing mAbs in patients

The urgency and scale of the coronavirus outbreak could drive progress in an emerging therapeutic strategy suited to rapid development and distribution -- encoding of antibodies in RNA or DNA. Neutralizing mAbs against SARS-CoV-2 have...
BioCentury | Apr 1, 2020
Finance

Pandion’s immune-regulating platform attracts $80M B round

Pandion raised $80 million in a series B round, triggered by a pancreas-focused partnership with Astellas and the clinical debut of its lead immune modulator. The modularity attracted Access Biotechnology to co-lead the round with...
BioCentury | Mar 26, 2020
Regulation

FDA finally approves ozanimod for MS, satisfying first criterion for Bristol-Celgene CVR; launch delayed due to COVID-19

FDA’s approval of Celgene’s multiple sclerosis drug Zeposia ozanimod represents the first domino to fall among three that could lead to a big payout for Celgene’s former shareholders, who would be owed a contingent value...
BioCentury | Mar 26, 2020
Product Development

COVID-19 roundup: Grifols partners with BARDA, FDA on convalescent plasma; plus Vir, Sorrento, Ascletis, BMS and Ipsen

On the heels of FDA guidance for compassionate use of convalescent plasma for COVID-19, Grifols announced on Wednesday a partnership with the U.S. government to develop the therapy. Meanwhile, Vir and Sorrento are advancing their...
BioCentury | Mar 24, 2020
Product Development

Positive data for intrathecally delivered Zolgensma could broaden its patient population

The latest data on Novartis’ Zolgensma could help solidify and possibly expand the gene therapy’s position in the SMA market as the company prepares for a potential new entrant in the coming months. During a...
BioCentury | Mar 20, 2020
Finance

COVID stocks spike as market volatility continues

As the broader markets continue to tumble amidst the COVID-19 pandemic, several biotechs at the center of the race to develop countermasures have seen their valuations swing wildly since the crisis began to unfold in...
BioCentury | Mar 20, 2020
Emerging Company Profile

Eikonizo: brain-penetrant HDAC inhibitors for neurodegeneration

Eikonizo aims to shore up axonal transport to treat neurodegenerative diseases, starting with ALS; and to de-risk its programs, the company is developing a companion PET tracer to confirm target engagement in vivo.   The...
BioCentury | Mar 19, 2020
Product Development

Trials, in-hospital treatments and guidances hit snags in the wake of COVID-19

As vaccine and therapeutic companies ramp up clinical trials for COVID-19, other biotechs are halting trials to protect patients and to preserve hospital resources. The ripple effects of the pandemic are also beginning to play...
Items per page:
1 - 10 of 4851